Anti-cancer treatments for malignant lymphoma, including anthracyclines and cyclophosphamide, induce significant cardiotoxicity through mechanisms like mitochondrial dysfunction and oxidative stress.
Understanding the molecular mechanisms of cardiotoxicity from lymphoma treatments may unveil new targets for cardioprotective therapies.
Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology.
Řiháčková et al. (Wed,) conducted a review in Malignant lymphoma. Anti-cancer therapy (chemotherapy and radiotherapy) was evaluated. Anti-cancer treatments for malignant lymphoma, including anthracyclines and cyclophosphamide, induce significant cardiotoxicity through mechanisms like mitochondrial dysfunction and oxidative stress.